FDA Finally OKs Twice-Rejected Melanoma Drug

(MedPage Today) -- The FDA granted accelerated approval to vusolimogene oderparepvec (Tudriqev), known as RP1, in combination with nivolumab (Opdivo) to treat adults with unresectable advanced cutaneous melanoma, the agency announced Thursday...